FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324491134> ?p ?o ?g. }

• W2324491134 abstract "Event Abstract Back to Event Design of targeted MRI contrast agents for early cancer detection Zhengrong Lu1 1 Case Western Reserve University, Biomedical Engineering, United States Introduction: Molecular imaging of high-risk cancer with metastatic potential has a potential to detect the life threatening disease earlier, to guide better treatment design, and to timely monitor therapeutic response. We have designed and tested small molecular targeted Gd(III) based MRI contrast agents to target fibronectin, a hallmark of EMT, highly expressed in the ECM of aggressive tumors for early detection and differential diagnosis of high-risk cancer, including breast cancer and prostate cancer. Materials and Methods: Targeted MRI contrast agents are synthesized by the conjugation of small peptides specific to the biomarkers to macrocyclic Gd(III) chelates Gd-DOTA or Gd(HP-DO3A). The expression of the biomarkers in tumor was determined by western blot. The binding of the peptides was determined by fluorescence imaging. The effectiveness of the targeted MRI contrast agents for cancer molecular imaging has been tested in mice bearing prostate cancer or metastatic breast cancer on a Bruker 7T animal MRI scanner. The ability of the targeted MRI contrast agents in detecting microscopic tumors was validated by cryo-imaging. Results: Fibronectin, especially oncofetal fibronectin, is highly expressed in high-risk tumors. The peptides specifically bound to the molecular targets in tumor ECM. The targeted contrast agents produced strong tumor enhancement for effective tumor detection with MRI. MRI with the targeted contrast agents was able to detect breast cancer micrometastases with a size as small as 300 microns, which is validated by fluorescence cryo-imaging. The targeted contrast agents are also able to monitor the growth of detected metastases with MRI. Conclusion: Small molecular peptide targeted MRI contrast agents specific to fibronectin and oncofetal fibronectin are effective to produce strong contrast enhancement in cancer and micrometastases for early cancer detection with MRI. They have the potential for clinical translation in detection and clinical management of high-risk cancer. Keywords: Molecular Imaging, MRI, contrast agent Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016. Presentation Type: New Frontier Oral Topic: Imaging with biomaterials Citation: Lu Z (2016). Design of targeted MRI contrast agents for early cancer detection. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.00562 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 27 Mar 2016; Published Online: 30 Mar 2016. Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Zhengrong Lu Google Zhengrong Lu Google Scholar Zhengrong Lu PubMed Zhengrong Lu Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page." @default.
• W2324491134 created "2016-06-24" @default.
• W2324491134 creator A5054774521 @default.
• W2324491134 date "2016-01-01" @default.
• W2324491134 modified "2023-10-18" @default.
• W2324491134 title "Design of targeted MRI contrast agents for early cancer detection" @default.
• W2324491134 doi "https://doi.org/10.3389/conf.fbioe.2016.01.00562" @default.
• W2324491134 hasPublicationYear "2016" @default.
• W2324491134 type Work @default.
• W2324491134 sameAs 2324491134 @default.
• W2324491134 citedByCount "0" @default.
• W2324491134 crossrefType "journal-article" @default.
• W2324491134 hasAuthorship W2324491134A5054774521 @default.
• W2324491134 hasBestOaLocation W23244911341 @default.
• W2324491134 hasConcept C118646709 @default.
• W2324491134 hasConcept C121608353 @default.
• W2324491134 hasConcept C126322002 @default.
• W2324491134 hasConcept C126838900 @default.
• W2324491134 hasConcept C136339569 @default.
• W2324491134 hasConcept C142724271 @default.
• W2324491134 hasConcept C143409427 @default.
• W2324491134 hasConcept C150903083 @default.
• W2324491134 hasConcept C207001950 @default.
• W2324491134 hasConcept C2780192828 @default.
• W2324491134 hasConcept C2781230642 @default.
• W2324491134 hasConcept C502942594 @default.
• W2324491134 hasConcept C530470458 @default.
• W2324491134 hasConcept C71924100 @default.
• W2324491134 hasConcept C86803240 @default.
• W2324491134 hasConceptScore W2324491134C118646709 @default.
• W2324491134 hasConceptScore W2324491134C121608353 @default.
• W2324491134 hasConceptScore W2324491134C126322002 @default.
• W2324491134 hasConceptScore W2324491134C126838900 @default.
• W2324491134 hasConceptScore W2324491134C136339569 @default.
• W2324491134 hasConceptScore W2324491134C142724271 @default.
• W2324491134 hasConceptScore W2324491134C143409427 @default.
• W2324491134 hasConceptScore W2324491134C150903083 @default.
• W2324491134 hasConceptScore W2324491134C207001950 @default.
• W2324491134 hasConceptScore W2324491134C2780192828 @default.
• W2324491134 hasConceptScore W2324491134C2781230642 @default.
• W2324491134 hasConceptScore W2324491134C502942594 @default.
• W2324491134 hasConceptScore W2324491134C530470458 @default.
• W2324491134 hasConceptScore W2324491134C71924100 @default.
• W2324491134 hasConceptScore W2324491134C86803240 @default.
• W2324491134 hasLocation W23244911341 @default.
• W2324491134 hasOpenAccess W2324491134 @default.
• W2324491134 hasPrimaryLocation W23244911341 @default.
• W2324491134 hasRelatedWork W2047035468 @default.
• W2324491134 hasRelatedWork W2060481892 @default.
• W2324491134 hasRelatedWork W2292727548 @default.
• W2324491134 hasRelatedWork W2758639219 @default.
• W2324491134 hasRelatedWork W2803841817 @default.
• W2324491134 hasRelatedWork W2809002819 @default.
• W2324491134 hasRelatedWork W2904294837 @default.
• W2324491134 hasRelatedWork W3029122078 @default.
• W2324491134 hasRelatedWork W3147647031 @default.
• W2324491134 hasRelatedWork W377899687 @default.
• W2324491134 hasVolume "4" @default.
• W2324491134 isParatext "false" @default.
• W2324491134 isRetracted "false" @default.
• W2324491134 magId "2324491134" @default.
• W2324491134 workType "article" @default.